Agilent Technologies (A) — Tellvest

Top Analysts & Firms

Most Active Analysts

Analyst	Firm	Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
Vijay Kumar	Evercore ISI	15 (20%)
Mike Ryskin	Bank of America	14 (7%)
Patrick Donnelly	Citigroup	14 (0%)
Dan Leonard	RBC Capital Markets	14 (7%)
Puneet Souda	Leerink Partners	13 (8%)
Tycho Peterson	Jefferies	12 (8%)
Jack Meehan	Operon Research	11 (0%)
Dan Brennan	TD Cowen	11 (0%)
Brandon Couillard	Wells Fargo	10 (0%)
Doug Schenkel	Wolfe Research	9 (22%)

Most Active Firms

Firm	Analysts	Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
Evercore ISI	1	15 (20%)
Jefferies	2	14 (7%)
RBC Capital Markets	1	14 (7%)
Citigroup	1

Latest Quarter Insights

2026 Q2

Sentiment

8/10+2.0

How this score was built

Base7Transcript0EPS0Guidance+1Final8

How this score was built

Base7Transcript0

Macro Signals

↑Enterprise Spending→Trade & Tariffs↑AI & Tech

Agilent delivered a strong Q2 with $1.83 billion in revenue growing 6.3% core, beating guidance by 80 basis points on broad-based instrument strength including low double digit LC, LCMS, and GC growth. The Ignite operating system drove 130 basis points of operating margin expansion to 26.4% through strategic pricing of approximately 200 basis points and manufacturing overhead reduction exceeding 50 basis points. Management raised full-year EPS guidance by $0.08 to $6.00-$6.10 and core growth guidance by 30 basis points to 4.5-6.0%, reflecting healthy demand in pharma, strong semiconductor-driven CAM growth of 8%, and continued instrument replacement cycle momentum offset by China softness and food market weakness in Asia.

Key Themes7

positive📊 company

Broad-Based Revenue Beat Driven By Instrument Strength

Revenue of $1.83 billion grew 6.3% core, exceeding guidance high end by 80 basis points. Instruments grew high single digits with LC, LCMS, and GC each delivering low double digit growth.

Revenue GrowthDemand

positive📊 company

Ignite Operating System Drives Margin Expansion

Operating margin of 26.4% expanded 130 basis points year over year and 180 basis points sequentially. Strategic pricing delivered approximately 200 basis points in Q2. Manufacturing overhead reduced by more than 50 basis points versus last year.

MarginCost Pressure

positive📊 company

Instrument Replacement Cycle Continues Ninth Quarter

Q&A Topicsfrequency by quarter

	Demand	Revenue Growth	Margin	Macroeconomic	Guidance Reliability	Product Launch	Capex Investment	Geographic Expansion
2024Q4	10	6	2	5	4	4	2	3
2025Q1	8	4	4	4	1	2	1	2
2025Q2	7	3	4	1	2	2	2	2
2025Q3	8	4	5	1	4	2	2	2
2025Q4	11	4	3	2	3	3	4	2
2026Q1	11	6	4	2	4	1	3	1
2026Q2	13	3	2	4	1	2	1

	'24Q4	'25Q1	'25Q2	'25Q3	'25Q4	'26Q1	'26Q2
Demand	10	8	7	8	11	11	13
Revenue Growth	6	4	3	4	4	6	3
Margin	2	4	4	5	3	4	2
Macroeconomic	5	4	1	1	2	2	4
Guidance Reliability	4	1	2	4	3	4	1
Product Launch	4	2	2	2	3	1	2
Capex Investment	2	1	2	2	4	3	1
Geographic Expansion	3	2	2	2	2	1

Analyst Q&A10 analysts · 16 questions

Casey WoodringJPMorgan

would be curious to hear how much that forensic TSA 1-timer you called out was in the quarter. Was that baked into the guide

View in transcript →

Catherine SchulteRobert W. Baird

just given that was the 1 part of the guide that came down. You talked about delays in China and India

View in transcript →

Dan Brennan

View Healthcare sector trends →View Medical - Diagnostics & Research industry trends →

Key financialsFY2026 Q2

Reported GAAP figures from SEC filings

Quarter	Revenue	Rev YoY	EPS	EPS YoY	Op margin	Net margin	FCF
FY2024 Q4	$1.70B	+0.8%	$1.22	-24.7%	24.0%	20.6%	$388M
FY2025 Q1	$1.68B	+1.4%	$1.11	-5.9%	22.4%	18.9%	$334M
FY2025 Q2	$1.67B	+6.0%	$0.75	-28.6%	18.0%	12.9%

Industry Peersas of Q2 2026

Medical - Diagnostics & Research

Company	Score	Rev YoY	Headline
A Agilent Technologies	8	+10.0%	Agilent delivered a strong Q2 with $1.83 billion in revenue growing 6.3% core, beating guidance by 80 basis points on broad-based instrument strength including low double digit LC, LCMS, and GC growth
CRL Charles River Laboratories	4	-2.7%	Charles River returned to organic revenue growth for the first time since the third quarter of 2023, with total-company organic revenue up 0.1% (reported revenue lower on completed divestitures) and non-GAAP EPS of $3.02 topping the prior outlook
DGX Quest Diagnostics	8	+10.2%	Quest Diagnostics delivered a strong second quarter, growing consolidated revenue 10.2% (10% organic) on a 13.1% increase in requisition volume across its physician, hospital and consumer channels, aided by the Corewell Health and Fresenius Medical Care collaborations
DHR Danaher Corporation	6	+5.5%	Danaher delivered a better-than-expected second quarter, with sales of $6.3 billion and core revenue up 3%; excluding respiratory testing, core growth was 4.5%, a 150 basis point acceleration from the first quarter
IDXX Idexx Laboratories	8	+9.7%	IDEXX grew revenue about 10% as reported and 9% organically, delivering reported EPS of $4.27 (up 18% as reported and 15% on a comparable basis) as CAG Diagnostics recurring revenue rose 10.3% organically and comparable operating margin expanded 110 basis points
IQV IQVIA	8	+8.7%	IQVIA's second quarter revenue of $4.368 billion grew 8.7% on a reported basis and 8.5% at constant currency, with organic growth accelerating to 6%, three times the rate delivered a year ago
LH LabCorp	8	+5.8%	Enterprise revenue grew 5.8% to $3.7 billion with adjusted EPS of $4.99, up 14.9%, as adjusted operating margin expanded 70 basis points to 15.8% in what management called the fifth consecutive quarter of margin expansion across both segments
MTD Mettler Toledo	7	+4.5%	Mettler-Toledo delivered a strong beat-and-raise quarter, with sales of $1 billion up 7% in U.S
RVTY Revvity	6	+1.3%	Revvity delivered a beat-and-raise second quarter, with pro forma organic growth of 3% and pro forma adjusted EPS of $1.41 both above the high end of guidance, though about half the EPS upside came from $16 million of one-time tariff refunds and much of the rest from tax timing
TMO Thermo Fisher Scientific	8	+10.5%	Thermo Fisher delivered a broad-based beat, with reported revenue up 10% to $11.99 billion (5% organic) and GAAP EPS of $4.68, up 9%; adjusted EPS rose 13% to $6.03
WAT Waters Corporation	7	+113.3%	Waters delivered total revenue of $1.645 billion in its first full quarter owning the acquired Biosciences and Diagnostic Solutions businesses, composed of $828 million organic (+7% as reported, +9% constant currency, above the high end of guidance) and $817 million from the acquired units, which grew 4% as reported and beat guidance by $15 million

Shared themes this quarter

ACRDGDHIDIQLHMTRVTMWA

Demand

ACRDGDHIDIQLHMTRV

Macro signal alignment

Enterprise Spending

↑ A↑ CRL↑ DHR↑ IQV↑ MTD↑ RVTY↑ TMO↑ WAT

IDXX↓ IQV↑ LH TMO↓ WAT

AI & tech

↑ A

Agilent Technologies

Top Analysts & Firms

Most Active Analysts

Most Active Firms

Latest Quarter Insights

Q&A Topicsfrequency by quarter

Key financialsFY2026 Q2

Companies A discussed